Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.

Schaer DA, Geeganage S, Amaladas N, Lu ZH, Rasmussen ER, Sonyi A, Chin D, Capen A, Li Y, Meyer CM, Jones BD, Huang X, Luo S, Carpenito C, Roth KD, Nikolayev A, Tan B, Brahmachary M, Chodavarapu K, Dorsey FC, Manro JR, Doman TN, Donoho GP, Surguladze D, Hall GE, Kalos M, Novosiadly RD.

Clin Cancer Res. 2019 Aug 13. doi: 10.1158/1078-0432.CCR-19-0433. [Epub ahead of print]

PMID:
31409612
2.

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M.

J Immunother Cancer. 2018 Jun 4;6(1):45. doi: 10.1186/s40425-018-0354-6.

3.

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.

Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M.

J Immunother Cancer. 2018 Apr 30;6(1):31. doi: 10.1186/s40425-018-0329-7. Erratum in: J Immunother Cancer. 2018 Jun 4;6(1):45.

4.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, Wang YC, Rasmussen ER, Chin D, Capen A, Carpenito C, Staschke KA, Chung LA, Litchfield LM, Merzoug FF, Gong X, Iversen PW, Buchanan S, de Dios A, Novosiadly RD, Kalos M.

Cell Rep. 2018 Mar 13;22(11):2978-2994. doi: 10.1016/j.celrep.2018.02.053.

5.

Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.

Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, Neal LR, Shirai K, Carpenito C, June CH, Zilliox MJ, Paulos CM.

Nat Commun. 2017 Dec 6;8(1):1961. doi: 10.1038/s41467-017-01867-9.

6.

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH.

Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19.

7.

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD Jr, Scholler J, Scholler N, Bonneau R, June CH.

Blood. 2014 Aug 14;124(7):1070-80. doi: 10.1182/blood-2013-10-535245. Epub 2014 Jul 1.

8.

Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing.

Eaker S, Armant M, Brandwein H, Burger S, Campbell A, Carpenito C, Clarke D, Fong T, Karnieli O, Niss K, Van't Hof W, Wagey R.

Stem Cells Transl Med. 2013 Nov;2(11):871-83. doi: 10.5966/sctm.2013-0050. Epub 2013 Oct 7. Review.

9.

Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, Plesa G, Zheng Z, Cotte J, Carpenito C, Wood T, Spratt SK, Ando D, Gregory P, Holmes MC, Perez EE, Riley JL, Carroll RG, June CH, Levine BL.

Hum Gene Ther. 2013 Mar;24(3):245-58. doi: 10.1089/hum.2012.172. Epub 2013 Mar 6.

10.

A human memory T cell subset with stem cell-like properties.

Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP.

Nat Med. 2011 Sep 18;17(10):1290-7. doi: 10.1038/nm.2446.

11.

Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, June CH, Grupp SA, Reid GS.

Blood. 2011 Oct 13;118(15):e112-7. doi: 10.1182/blood-2011-04-346528. Epub 2011 Aug 19.

12.

Treatment of advanced leukemia in mice with mRNA engineered T cells.

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA.

Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23.

13.

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.

Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr, Riley JL, June CH, Albelda SM.

Clin Cancer Res. 2011 Jul 15;17(14):4719-30. doi: 10.1158/1078-0432.CCR-11-0351. Epub 2011 May 24.

14.

Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.

Alagkiozidis I, Facciabene A, Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, June CH, Powell DJ Jr, Coukos G.

J Transl Med. 2011 May 25;9:77. doi: 10.1186/1479-5876-9-77.

15.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr.

Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5.

16.

The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.

Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH.

Sci Transl Med. 2010 Oct 27;2(55):55ra78. doi: 10.1126/scitranslmed.3000448.

17.

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.

Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5.

18.

Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.

Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, Carroll RG, Gimotty PA, Hammond R, Danet-Desnoyers GÄ, June CH, Powell DJ Jr, Coukos G.

J Transl Med. 2009 Dec 10;7:104. doi: 10.1186/1479-5876-7-104.

19.

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH.

Mol Ther. 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278.

20.

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5. doi: 10.1073/pnas.0813101106. Epub 2009 Feb 11.

21.

Genetic engineering of T cells for adoptive immunotherapy.

Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL.

Immunol Res. 2008;42(1-3):166-81. doi: 10.1007/s12026-008-8057-6. Review.

22.

Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells.

Carroll RG, Carpenito C, Shan X, Danet-Desnoyers G, Liu R, Jiang S, Albelda SM, Golovina T, Coukos G, Riley JL, Jonak ZL, June CH.

PLoS One. 2008 Sep 26;3(9):e3289. doi: 10.1371/journal.pone.0003289.

23.

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.

Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH.

Nat Biotechnol. 2008 Jul;26(7):808-16. doi: 10.1038/nbt1410. Epub 2008 Jun 29.

24.

Expression of murine killer immunoglobulin-like receptor KIRL1 on CD1d-independent NK1.1(+) T cells.

Wilson EB, Parachoniak CA, Carpenito C, Mager DL, Takei F.

Immunogenetics. 2007 Aug;59(8):641-51. Epub 2007 May 22.

PMID:
17516061
25.

Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation.

Maeda M, Carpenito C, Russell RC, Dasanjh J, Veinotte LL, Ohta H, Yamamura T, Tan R, Takei F.

J Immunol. 2005 Oct 1;175(7):4426-32.

26.
27.

Identification of sequence motifs responsible for the adhesive interaction between exon v10-containing CD44 isoforms.

Hayes GM, Chiu R, Carpenito C, Dougherty ST, Dougherty GJ.

J Biol Chem. 2002 Dec 27;277(52):50529-34. Epub 2002 Oct 28.

28.

Alternative splicing as a novel of means of regulating the expression of therapeutic genes.

Hayes GM, Carpenito C, Davis PD, Dougherty ST, Dirks JF, Dougherty GJ.

Cancer Gene Ther. 2002 Feb;9(2):133-41.

30.

Alternatively spliced CD44 isoforms containing exon v10 promote cellular adhesion through the recognition of chondroitin sulfate-modified CD44.

Chiu RK, Droll A, Dougherty ST, Carpenito C, Cooper DL, Dougherty GJ.

Exp Cell Res. 1999 Apr 10;248(1):314-21.

PMID:
10094837
31.
32.

ICAM-2 provides a costimulatory signal for T cell stimulation by allogeneic class II MHC.

Carpenito C, Pyszniak AM, Takei F.

Scand J Immunol. 1997 Mar;45(3):248-54.

33.

Characterization of murine intercellular adhesion molecule-2.

Xu H, Bickford JK, Luther E, Carpenito C, Takei F, Springer TA.

J Immunol. 1996 Jun 15;156(12):4909-14.

PMID:
8648141
35.

Molecular cloning of murine intercellular adhesion molecule (ICAM-1).

Horley KJ, Carpenito C, Baker B, Takei F.

EMBO J. 1989 Oct;8(10):2889-96.

Supplemental Content

Loading ...
Support Center